Current Report Filing (8-k)
December 16 2022 - 5:11PM
Edgar (US Regulatory)
0001401914
false
Dare Bioscience, Inc.
0001401914
2022-12-16
2022-12-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): December 16, 2022
DARÉ
BIOSCIENCE, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-36395 |
|
20-4139823 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
No.) |
3655
Nobel Drive, Suite 260
San
Diego, CA 92122
(Address
of Principal Executive Offices and Zip Code)
Registrant’s
telephone number, including area code: (858) 926-7655
Not
Applicable
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
stock |
|
DARE |
|
Nasdaq
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
3.01 |
Notice
of Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
On
December 16, 2022, Daré Bioscience, Inc. (“Daré”) received a letter from the Listing Qualifications Department
(the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying Daré that, for the last 30 consecutive business
days, the closing bid price for Daré’s common stock was below the minimum $1.00 per share requirement for continued listing
on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Nasdaq
letter has no immediate effect on the listing of Daré’s common stock on the Nasdaq Capital Market.
In
accordance with Nasdaq listing rules, Daré has been provided an initial period of 180 calendar days, or until June 14, 2023
(the “Compliance Date”), to regain compliance with the Minimum Bid Price Requirement. If, at any time during this 180-day
period, the closing bid price of Daré’s common stock is at least $1.00 for a minimum of 10 consecutive business days, unless
the Staff exercises its discretion to extend such 10-day period, the Staff will provide Daré written confirmation of compliance
with the Minimum Bid Price Requirement and the matter will be closed. If Daré does not regain compliance by the Compliance Date,
Daré may be eligible for an additional 180 calendar day compliance period. To qualify for such additional compliance period, Daré
would have to meet the continued listing requirement for the market value of publicly held shares and all other initial listing standards
for The Nasdaq Capital Market, except for the Minimum Bid Price Requirement, and Daré would need to provide written notice of its
intention to cure the deficiency during the additional compliance period, by effecting a reverse stock split, if necessary. If Daré
is not eligible for the additional compliance period or it appears to the Staff that Daré will not be able to cure the deficiency
or if the Staff exercises its discretion to not provide such additional compliance period, the Staff will provide written notice to Daré
that its common stock will be subject to delisting. At that time, Daré may appeal the Staff’s delisting determination to a
Nasdaq Hearing Panel.
Daré
will monitor the closing bid price of its common stock and will consider options to regain compliance with the Minimum Bid Price Requirement.
There can be no assurance that Daré will regain compliance with the Minimum Bid Price Requirement or maintain compliance with
any of the other Nasdaq continued listing requirements.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
DARÉ
BIOSCIENCE, INC. |
|
|
|
Dated:
December 16, 2022 |
By: |
/s/
Sabrina Martucci Johnson |
|
Name: |
Sabrina
Martucci Johnson |
|
Title: |
President
and Chief Executive Officer |
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Jul 2023 to Jul 2024